Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15688938 | 0.93 | NPC1 (0.41) | NPC1RAB9ACA12CA9NPSR1 | |
| SCHEMBL1964253 | 0.93 | AKR1C1 (0.43) | NPC1RAB9ACA12CA9NPSR1 | |
| SCHEMBL372682 | 0.91 | AKR1C1 (0.42) | NPC1RAB9ACA12CA9NPSR1 | |
| SCHEMBL17113633 | 0.91 | AKR1C1 (0.42) | NPC1RAB9ACA12CA9NPSR1 | |
| SCHEMBL14830423 | 0.85 | NPC1 (0.49) | NPC1RAB9ACA12CA9NPSR1 | |
| SCHEMBL16096494 | 0.84 | NPC1 (0.43) | NPC1RAB9ACA12CA9NPSR1 | |
| SCHEMBL185865 | 0.84 | NPC1 (0.40) | NPC1RAB9ACA12CA9NPSR1 | |
| SCHEMBL28813798 | 0.82 | LMNA (0.45) | NPC1RAB9ACA12CA9NPSR1 | |
| SCHEMBL15111158 | 0.81 | OPRM1 (0.51) | NPC1RAB9ACA12CA9NPSR1 | |
| SCHEMBL16095167 | 0.81 | OPRM1 (0.46) | NPC1RAB9ACA12CA9NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-09 | — | — | US | disclosed |
| US-10138256-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-11-27 | — | — | US | disclosed |
| EP-2968339-A1 | MK2 INHIBITORS AND USES THEREOF | Celgene Avilomics Research, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-12-31 | — | — | US | disclosed |
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | UNIV EMORY (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014149164-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2760820-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | Emory University (US) | 2014-08-06 | — | — | EP | disclosed |
| CN-103958457-A | Sphingosine analogs, compositions, and methods related thereto | UNIV EMORY | 2014-07-30 | — | — | CN | disclosed |
| WO-2013049280-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049280-A2 | SPHINGOSINE ANALOGS, COMPOSITIONS, AND METHODS RELATED THERETO | EMORY UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376208-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | NPC1 3265/4885RAB9A 3788/4885CA12 2467/4885 |
| US-10138256-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | NPC1 3265/4885RAB9A 3788/4885CA12 2467/4885 |
| US-20140309275-A1 | Sphingosine Analogs, Compositions, and Methods Related Thereto | SPHK1, S1PR1, S1PR2 | NPC1 499/4885RAB9A 1163/4885CA12 2848/4885 |
| US-20190135835-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | NPC1 3265/4885RAB9A 3788/4885CA12 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.